HB Wealth Management LLC Boosts Stock Position in Halozyme Therapeutics, Inc. $HALO

HB Wealth Management LLC lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 281.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 14,202 shares of the biopharmaceutical company’s stock after purchasing an additional 10,483 shares during the period. HB Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $1,112,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in HALO. Empowered Funds LLC acquired a new position in Halozyme Therapeutics during the first quarter worth $755,000. Acadian Asset Management LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter worth $195,000. Hsbc Holdings PLC boosted its position in shares of Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. grew its holdings in shares of Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 32,478 shares of company stock worth $3,076,604. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 0.4%

Shares of HALO opened at $107.00 on Friday. The company’s 50-day moving average price is $93.18 and its 200 day moving average price is $76.75. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $111.15. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The firm has a market cap of $12.14 billion, a P/E ratio of 31.94, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter last year, the firm posted $1.54 earnings per share. Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.98 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HALO shares. TD Cowen lifted their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.